Brad Bhatt

Brad Bhatt specializes in the use of checkpoint inhibitors for relapsed and refractory Hodgkin lymphoma, which is uniquely sensitive to PD-1 blockade due to 9p24.1 amplification causing PD-L1 overexpression. His research has characterized the molecular basis of Hodgkin lymphoma's exquisite sensitivity to nivolumab and pembrolizumab. He has also studied checkpoint inhibitor consolidation after autologous and allogeneic stem cell transplantation. His translational work is defining the role of checkpoint inhibitors in the Hodgkin lymphoma treatment algorithm.